Who are low dose Astragalus's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): American ginseng root / polysaccharides, Ginseol Kg1 (low dose).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/low-dose-astragalus.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

low dose Astragalus — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

low dose Astragalus (low dose Astragalus) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Herbal extract / Immunomodulator. Area: Immunology / Regenerative Medicine.

phase 3 Herbal extract / Immunomodulator Immunology / Regenerative Medicine Small molecule Live · refreshed every 30 min

Target snapshot

low dose Astragalus (low dose Astragalus) — LanZhou University. Low-dose Astragalus enhances immune function and promotes tissue repair through polysaccharide and saponin constituents that stimulate immune cell activity and growth factor production.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
low dose Astragalus TARGET	low dose Astragalus	LanZhou University	phase 3	Herbal extract / Immunomodulator
American ginseng root / polysaccharides	American ginseng root / polysaccharides	Risk Factor Modification Centre	phase 3	Herbal extract / Immunomodulator
Ginseol Kg1 (low dose)	Ginseol Kg1 (low dose)	Seoul National University Hospital	phase 3	Herbal extract / Immunomodulator

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Herbal extract / Immunomodulator class)

LanZhou University · 1 drug in this class
Risk Factor Modification Centre · 1 drug in this class
Seoul National University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). low dose Astragalus — Competitive Intelligence Brief. https://druglandscape.com/ci/low-dose-astragalus. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing